Alternative splicing is a key process required for the regulation of gene expression in normal development and physiology. It is regulated by splice factors whose activities are in turn regulated by splice factor kinases and phosphatases. The CDC-like protein kinases are a widespread family of splice factor kinases involved in normal physiology and in several diseases including cancer. In humans they include the CLK1, CLK2, CLK3 and CLK4 genes. The expression of CLK1 is regulated through alternative splicing producing both full-length catalytically active and truncated catalytically inactive isoforms, CLK T1 (arising from exon 4 skipping) and CLK T2 (arising from intron 4 retention). We examined CLK1 alternative splicing in a range of cancer cell lines, and report widespread and highly variable rates of exon 4 skipping and intron 4 retention. We also examined the effect of severe environmental stress including heat shock, osmotic shock, and exposure to the alkaloid drug harmine on CLK1 alternative splicing in DU145 prostate cancer cells. All treatments rapidly eliminated exon 4 skipping and intron 4 retention, shifting the balance towards full-length CLK1 expression. We also found that the inhibition of CLK1 with the benzothiazole TG003 also eliminated exon 4 skipping and intron 4 retention suggesting an autoregulatory mechanism. CLK1 inhibition with TG003 also resulted in modified alternative splicing of five cancer-associated genes.
Introduction
The CLK (CDC-2 like) protein kinases phosphorylate splice factors and contribute significantly to the regulation of alternative splicing. The CLK1 gene was first identified in 1991 through a homology probing approach (Johnson and Smith, 1991) . The full-length protein it encodes is 484 amino-acids long, of which the first 130 constitute a regulatory region required for the interaction of CLK1 with SR proteins (splice factors with a serine/arginine-rich domain). The remaining amino-acids form the catalytic domain containing the conserved signature phosphorylate the so-called 'SR protein' splice factors, facilitating their activation and release from nuclear speckles (Naro and Sette, 2013) . However CLK kinases can also phosphorylate non-SR protein splice factors including the spliceosome-associated SPF45 (Liu et al., 2013) .
CLK activity is increasingly associated with the development and progression of cancer (Naro and Sette, 2013; Corkery et al., 2015; Czubaty and Piekielko-Witknowska, 2017) . As a result there is considerable interest in developing selective CLK inhibitors that block tumour growth (Schmitt et al., 2014; ElHady et al., 2017; Murar et al., 2017; Sun et al., 2017; Riggs et al., 2017; Walter et al., 2017) . CLK1 is also a potential target in the treatment of Alzheimer's (Jain et al., 2014) and has been earmarked for the treatment of Duchenne's muscular dystrophy as its inhibition causes the skipping of a mutated exon (Ogawa and Hagiwara, 2012; Sako et al., 2017) . CLK targeting has also been proposed for the treatment of viral infection including HIV-1 (Wong et al., 2011) and influenza (Karlas et al., 2010; Zu et al., 2015) .
The human CLK1 gene is comprised of 13 exons, and is alternatively spliced expressing either a full length or truncated protein that lacks the catalytic domain (Duncan et al., 1997;  synthesis was performed using reverse transcriptase and a mixture of oligo (dT) and random primers as per manufacturer's instructions (Promega). 1g RNA was mixed with 0.5µl of the oligo and 0.5µl random primers provided by the kit in a volume of 5.0µl with nuclease free water. The samples were placed in a heat block at 70 o C for five minutes, then chilled on ice for five minutes. To each 5µl RNA sample, 15µl of reverse transcription reaction mix was added. Primers were allowed to anneal at 25 0 C for 5 min, cDNA synthesis proceeded at 42 o C for one hour and finally the reverse transcriptase was inactivated at 70 o C for 15 min.
Polymerase chain reaction
cDNA was amplified with the GoTaq kit (Promega) as per manufacturer's instructions using the CLK1 primers (E3F1 CAAGGATGTGAACCTGGACATCGC and E4F1
GGAGGTCACCTGATCTGTCAG forward primers in exons 3 and 4 respectively, and reverse primers E5R1 CTCCTTCACCTAAAGTATCAAC and E5R2 CTGCTACATGTCTACCTCCCGC in exon 5, as well as -actin forward TTAAGGAGAAGCTGT and reverse GTTGAAGGTAGTTTCGTGGAT to verify cDNA synthesis; all sequences shown are 5′-3′). PCR cycles were as follows: 95 o C for 2 minutes (initial denaturation), then 95 o C for 1 min. (denaturation), 59 o C for 1 min.
(annealing), 72 o C for 1.5 min. (extension); cycles were repeated 34 times followed by a final extension step at 72 o C for 5 min.
Agarose gel electrophoresis
20l aliquots of amplified PCR products were run in 2% (w/v) agarose gel at 95V and 400AMP
for 1 hour. Agarose gels were stained in 0.2mg/ml ethidium bromide (Sigma-Aldrich). Gel images were obtained using UV transluminator (Fisher Scientific).
Statistical analysis
All statistical tests were performed using GraphPad Prism 7.03. Mann-Whitney t-tests were used to compare significance between two groups. For multiple comparisons, one-way ANOVAs with Kruskal-Wallis test were performed. For all graphs, n.s. denotes not significant, * = p ≤ 0.05, ** = p ≤ 0.01, *** = p ≤ 0.001.
Results

Features of CLK1's exon 4 and intron 4
We began by examining the exon/intron structure of the human CLK1 gene, focusing on exon 4 and surrounding intronic sequence (Fig. 1) . The structure of the human CLK1 gene mirrors closely that of the corresponding mouse gene, with a short intron separating exons 4 and 5 in both species and very high sequence conservation in exon 4 and flanking intron. Skipping of exon 4 has previously been reported in the human CLK1 gene (Duncan et al., 1997) , and both exon 4 skipping and intron 4 retention has been reported in the mouse gene (Ninomiya et al., 2011) . Exon 4 skipping results in a premature stop codon interrupting the amino-terminal regulatory domain, resulting in a truncated 120 amino-acid previously named CLK1 T (Duncan et al., 1997) . Intron 4 retention also creates a premature stop codon and a truncated CLK1, albeit a little longer (160 amino-acids). We propose to call the former CLK T1 (arising from exon 4 skipping) and the latter CLK1 T2 (due to intron 4 retention, Fig. 1A and 1B).
We analysed the exon 4 sequence on the RBPmap and SROOGLE servers (Paz et al., 2014; Schwart et al., 2009) and noted a number of interesting features (Fig. 1C) . Firstly, there is a weak pyrimidine tract with three purines preceding exon 4 (…CUUGACGUUUCCAG, consensus Y11NCAG, where Y is U or C). The 5′ splice site at the end of exon 4 is also not especially strong, GATguauag compared to the consensus MAGguragu where M is A or C and R is A or G. This suggests that the baseline efficiency of exon 4 recognition and splicing is likely to be low. In contrast the end intron 4 possesses a better pyrimidine tract (…UUCUCUCUUUUAG). This suggests that more efficient exon 4 inclusion may require the action of specific splice factors acting through exonic splice enhancers (ESEs). Using the SROOGLE server (sroogle.tau.ac.il)
we identified the presence of putative ESEs particularly at the beginning of exon 4 (Zhang and Chasin, 2004) ; these correspond to potential binding sites for splice factors SRSF1 and SRSF2, (Schwartz et al, 2008) . Additional potential splice factor binding sites were identified using RBPmap (Paz et al., 2014) , ESE finder (Cartegni et al., 2003) and SpliceAid (Piva et al., 2009) .
Exon 4 appears particularly dense with potential SRSF1 binding sites (Fig. 1C ). Through SROOGLE we also noted the presence of a potential intronic splice silencer (ISS) immediately following the 5′ splice site at the end of exon 4.
Alternative splicing of CLK1 in of cancer cell lines
Based on the reported skipping of exon 4 and retention of intron 4 in mouse embryo fibroblast-like NIH-3T3 cells (Ninomiya et al., 2011) we designed human-specific primers for
RT-PCR including a forward primer in exon 3 and in exon 4 and two reverse primers in exon 5 that could be used to detect these alternative splicing events (Fig. 1A) . Skipping of exon 4 had previously also been reported in the human embryonic kidney cell line 293T (Duncan et al., 1997) . We surveyed a range of human cell lines to look for evidence of CLK1 alternative splicing. We observed variable exon 4 skipping in all cell lines examined, and intron 4 retention in all but one cell line (Fig. 2 ). More specifically, alternative splicing of CLK1 was observed in PC3 and DU145 androgen-independent prostate cancer cell lines, and in androgen-dependent VCaP cells. CLK1 alternative splicing was also apparent in the normal prostate epithelium cell line PNT2, albeit with a higher degree of intron retention. We also observed alternative splicing of CLK1 in the cervical cancer cell line HeLa and in fetal kidney HEK293 cells ( Fig. 2A ).
We also examined CLK1 alternative splicing in a range of leukemic cell lines (Fig. 2B ). In the leukemic cell lines we observed widespread exon 4 skipping and intron 4 retention; however intron 4 retention was less prominent and was not detectable in MOLT4 acute lymphoblastic leukemia cells. In summary there is clear evidence that CLK1 is alternatively spliced in all cancer cell lines examined, but the degree of exon 4 skipping or intron 4 retention varies significantly.
Effect of heat shock, osmotic shock and harmine on CLK1 alternative splicing
Heat shock and osmotic stress (the latter through exposure to high concentrations of sorbitol)
were previously shown to promote the maturation of murine Clk1 mRNA (Ninomiya et al. 2011 ). We sought to determine whether or not the human CLK1 transcript is similarly affected. DU145 prostate cancer cells were grown at 42°C for one, three and six hours. After only one hour exon 4 skipping and intron 4 retention could not be detected (Fig. 3A) . We confirmed that increased exon 4 inclusion and decreased intron 4 retention corresponded, as expected, to increased CLK1 protein levels (Fig. 3B ). We exposed DU145 cells to osmotic stress in 200 and 400mM sorbitol. In these conditions we also observed a reduction in exon 4 skipping and loss of intron 4 retention (Fig. 3C) . We also treated DU145 cells with the drug harmine, a multifunctional alkaloid derived from the plant Peganum harmala that has a range of effects including antimicrobial, antitumour, and hallucinogenic (Patel et al., 2010; Moloudizargari et al., 2013) . Harmine is also a potent inhibitor of the splice factor DYRK1A (Göckler at al., 2009), and it causes changes in alternative splicing in vivo (Herrendorf et al., 2016) . DU145 cells were treated with 1-5M harmine for six hours. At the lowest concentration (1M) harmine entirely eliminated both exon 4 skipping and intron 4 retention.
Thus we confirm that, like mouse Clk1, the human CLK1 gene responds to heat shock and osmotic stress by promoting productive CLK1 splicing (mRNA that encodes full length CLK1), and the same effect is observed following exposure to the alkaloid harmine.
Effect of TG003-mediated CLK1 inhibition on alternative splicing
The benzothiazole compound TG003 was developed as a specific inhibitor of CLK1 (Muraki et al., 2004) . TG003 has previously been shown to promote productive CLK1 splicing in murine cells; we therefore sought to confirm this apparent autoregulatory effect in human cells.
DU145 prostate cancer cells were treated with a wide range of TG003 concentrations, 10nM
to 100M. A clear shift in alternative splicing could be observed at 100nM (Fig. 4A) . At the highest concentrations of TG003 no detectable exon 4 skipping or intron 4 retention was observed. We also examined CLK1 protein levels and observed that at the higher TG003 concentrations CLK1 protein levels clearly increased, consistent with the occurrence of more productive CLK1 splicing (Fig. 4B ).
The inhibition of CLK1 with TG003 has been shown to result in significant changes in global exon skipping rates (Sakuma et al., 2015) . We examined the effect of TG003 on the alternative splicing of four apoptosis-related genes, Bcl-X (Boise et al., 1993) , Mcl-1 (Bae et al., 2000) , survivin (Mahotka et al., 1999) and CASP9 (Srinivasula et al., 1999) as well as the cancerassociated gene FGFR10P (FGFR10 oncogene partner; Lee et al., 2013) . In all cases we observed clear changes in their alternative splicing, suggesting that the inhibition of CLK1 has a significant and widespread impact on alternative splicing of cancer-associated genes.
Discussion
The splice factor kinase CLK1, a member of the CDC2-like CLK family, contributes to the regulation of alternative splicing by phosphorylating SR proteins and other splice factors including the spliceosome-associated SPF45 (Liu et al., 2013) . The CLK1 gene is alternatively spliced (Duncan et al., 1997; Ninomiya et al., 2011) , producing both catalytically active and truncated, inactive CLK1, the latter as a result of exon 4 skipping (120 amino-acids long CLK1 T1 )
or intron 4 retention (160 amino-acids long CLK1 T2 ). CLK1 is increasingly linked to the pathobiology of several diseases, including neurological conditions, metabolic disorders and cancer. We examined the baseline alternative splicing of CLK1 in a range of human cancer cell lines, focusing on the skipping of exon 4 and retention of intron 4. We found evidence of widespread, and highly variable CLK1 alternative splicing in 12 cell lines. Whereas significant rates of exon 4 skipping could be detected in leukemic cell lines, intron 4 retention was less prominent than in the prostate cancer cell lines. Both types of CLK1 alternative splicing lead to the expression of truncated CLK1 T1 (exon 4 skipping) and CLK1 T2 (intron 4 retention), each lacking the catalytic domain. The presence of high levels of these CLK1 splice isoforms suggests that they are not entirely removed by nonsense-mediated decay (NMD). The ability of retained introns described as 'detained' introns to evade NMD has previously been reported (Boutz et al., 2015) . Detained introns are a special class of introns that are poorly spliced and retained in the nucleus in order to modulate gene expression (Fu, 2017; Wegener and Müller-McNicoll, 2017) . Interestingly, CLK1 itself has been shown to regulate the alternative splicing of nuclear 'detained' introns in hundreds of other genes (Boutz, Bhutkar & Sharp, 2015) . We suggest that the co-expression of truncated, catalytically inactive CLK1 is functionally required to maintain an appropriate level of CLK1 activity. Interestingly, our results show that CLK1 inhibition with TG003 alters the balance of pro-and anti-apoptotic splice isoforms of CASP9, MCL-1, BCL-X and survivin genes, suggesting that the baseline activity of CLK1 needs to be precisely maintained by cancer cells in order to prevent apoptosis.
Future work will determine whether or not the effect of TG003 on the alternative splicing of these genes is directly attributable to CLK1 inhibition or due to an indirect effect.
We confirm that the alternative splicing of CLK1 changes radically in response to severe environmental shock. We observe that heat shock, osmotic shock and harmine treatment all very rapidly lead to more efficient CLK1 splicing, producing higher levels of catalytically active CLK1. Heat shock has been shown to lead to rapid dephosphorylation of the SR protein SRp38
(SRSF10) by protein phosphatase 1 (Shi and Manley, 2007) . We note the presence of a putative SRSF10 binding site in exon 4 (Fig. 1C) . We suggest that the equally rapid shift to productive CLK1 splicing in heat shock helps to augment the phosphorylation of SR proteins.
The impact of harmine on the intron retention and exon skipping of CLK1 pre-mRNA had not been previously assessed (Ogawa & Hagiwara, 2012) . We show that exposure of DU145 cells to 1M harmine for six hours also promoted the maturation of CLK1 pre-mRNA. Interestingly, CLK1 expression is also induced in hypoxic cells (Eisenreich et al., 2013; Jakubauskiene et al., 2015; Bowler et al., 2018) . Activation of the CLK1 promoter occurs through hypoxia inducible factor (HIF-1); however the effect of hypoxia on CLK1 alternative splicing has not been examined. Taken together these findings indicate that cells need higher levels of catalytically active CLK1 to survive in conditions of extreme cellular stress.
We observed that inhibition of CLK1 with the benzothiazole TG003 also promoted productive CLK1 splicing and at higher concentrations increased levels of CLK1 protein. There are several precedents of splice factors that autoregulate their expression through alternative splicing;
these include Muscleblind-like 1 (MBNL1) (Gates et al., 2011) , the FOX splice factors (Damianov and Black, 2010) , and the SR proteins (Lareau and Brenner, 2015) including SRSF1 (Sun et al., 2010) . Analysis of exon 4 and flanking intronic sequence suggests that exon 4 is not flanked by strong splice sites, and that several SR proteins, including SRSF1, SRSF2 and SRSF10, may bind and contribute to the regulation of exon 4 inclusion. SRSF1 was the first splice factor to be described as a proto-oncogene (Karni et al., 2007) . SRSF1 is multifunctional, working at multiple levels of gene expression both in the nucleus and cytoplasm (Das and Krainer, 2014) . In regulating alternative splicing, SRSF1 can both promote (Lopez-Mejia et al., 2013) and repress (Jumaa and Nielsen, 2000) the inclusion of cassette exons. SRSF1 is also a well characterized substrate of CLK1. CLK1's N-terminal domain contacts SRSF1; this interaction is required for hyperphosphorylation of SRSF1 by CLK1 and facilitates SRSF1
binding to RNA targets (Aubol et al., 2014) . It is tempting to speculate that SRSF1 is involved in the autoregulation of CLK1 alternative splicing. There is also a potential TIA-1 binding site around the 3′ splice site; TIA-1 is involved in 3′ splice site recognition .
HnRNP H (Masuda et al., 2008 ) is often associated with splice silencers; there are also potential binding sites for this hnRNP protein in exon 4. Future research will determine precisely which splice factors are involved in CLK1 autoregulation through alternative splicing.
We suggest that CLK1 activity in both transformed and normal cells is carefully regulated via CLK1 alternative splicing through both exon 4 skipping and intron 4 retention. We suggest that CLK1 autoregulates its expression by favouring the expression of truncated isoforms, CLK1 T1 and CLK T2 ( Figure 5 ). Extreme environmental stress or CLK1 inhibition shifts the balance clearly towards productive splicing, increasing levels of full length CLK1. The function and regulation of expression of truncated splice isoforms CLK1 T1 and CLK T2 remains to be fully determined. Novel therapies that target CLK1 will need to take into account the presence of truncated CLK1 isofoms and the autoregulatory loop. Exon 4 and surrounding intronic sequences are shown below; three putative exonic splice enhancers (green) and an intronic splice silencer (red) were identified via SROOGLE (Schwartz et al., 2008) . 
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